Abstract 19P
Background
Vascular endothelial Growth factor (VEGF) has an important role in the physiology of normal ovaries and is a major player in the pathogenesis of OvCan. We have designed HEBERSaVax which is an active immunotherapy approach based on the use of a functionally deficient VEGF 121 isoform as antigen combined with an adjuvant. On immunocompetent mice, the ID8 model resembles the advanced stages of human OvCan and intervention results offer data potentially translatable to the clinical setting. Two sequential phase I clinical trials with single HEBERSaVax treatment have been concluded in patients with advanced solid tumors including subjects with advanced OvCan. A phase II clinical trial in this oncologic setting was recently finished. Herein we present data on HEBERSaVax effects on tumor development and reshaping of the microenvironment in OvCan.
Methods
C57BL/6 mouse tumor ID8 model was used to evaluate the vaccine effects in cancer growth control and tumor microenvironment remodeling. Immune response and cytokines concentrations were assessed by ELISA. Ascitic leukocytes were characterized by flow cytometry. Serum and leukocyte samples from selected OvCan patients (n=9) from the phase I clinical trials (RPCEC00000102 and RPCEC00000155) were also analyzed. Human anti-VEGF antibodies and cytokines were determined by ELISA. The cellular response was evaluated by IFN-γ ELISPOT.
Results
HEBERSaVax-based treatment increases the survival of ID8 tumor-bearing mice by reducing the ascites loads. An increase in VEGF-specific antibodies were detected in mice ascitic fluids, in parallel to a reduction of VEGF levels. The numbers of T lymphocytes and the expression of MHCII in macrophages were increased in the ascitic fluid. Data analyses from OvCan patients in clinical trials revealed that decreased or stabilized VEGF serum levels, positive anti-VEGF titers, and cellular responses, were related to an increase in survival. Processing of phase II clinical trial (RPCEC00000246) immune variables evaluations is ongoing (n=38, final data: ESMO).
Conclusions
Our findings indicate that HEBERSavax’s impact on preclinical ID8 settings might be translatable to a positive outcome in advanced OvCan patients.
Clinical trial identification
RPCEC00000102, RPCEC00000155 and RPCEC00000246.
Editorial acknowledgement
Legal entity responsible for the study
Center for Genetic Engineering and Biotechnology.
Funding
HEBERBiotec.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09